Literature DB >> 25040934

Everolimus in heart transplantation: does it finally have a home?

J A Kobashigawa, A O Zuckermann.   

Abstract

This editorial approves the use of everolimus to wean calcineurin inhibitors (by 7–11 weeks postoperative) as safe and effective with improved first-year renal function and reduced intimal thickness by intravascular ultrasound. See article by Andreassen et al on page 1828.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25040934     DOI: 10.1111/ajt.12805

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  1 in total

1.  Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients.

Authors:  Niklas Bergh; Einar Gude; Sven-Erik Bartfay; Arne K Andreassen; Satish Arora; Pia Dahlberg; Göran Dellgren; Lars Gullestad; Finn Gustafsson; Kristjan Karason; Göran Rådegran; Entela Bollano; Bert Andersson
Journal:  ESC Heart Fail       Date:  2020-02-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.